What Eli Lilly's $27B investment in US manufacturing means for GLP-1s
Mizuho healthcare equity strategist Jared Holz joins Julie Hyman and Josh Lipton on Market Domination to analyze the GLP-1 weight-loss drug market following Eli Lilly's (LLY) announcement of a substantial $27 billion investment in US manufacturing.
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for patients that don't have insurance.
Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...
1don MSN
We recently compiled a list of the 20 High Growth Mega Cap Stocks You Can Buy And Hold For Next 5 Years. In this article, we ...
Eli Lilly was second to the lucrative GLP-1 market for diabetes and obesity following its chief metabolic medicine rival Novo ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback